2 stocks I like better than CBA for long-term growth

Let's see why these buy-rated shares could be better picks than Australia's largest bank.

| More on:
Happy shareholders clap and smile as they listen to a company earnings report.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Commonwealth Bank of Australia (CBA) appears overpriced compared to peers, and its growth outlook is limited.
  • One alternative pick, offering scalable growth through recurring revenues, is a medical imaging software provider with a strong sales pipeline and expanding market reach.
  • Another opportunity lies in an online furniture retailer that stands to benefit from increasing online penetration and diversifying its product offerings.

Commonwealth Bank of Australia (ASX: CBA) might be one of the most popular shares on the ASX, but popularity doesn't always make a stock a good buy.

At today's share price, CBA looks expensive by almost any measure, trading at a significant premium to its banking peers and well above its historical valuation range.

In addition, while it remains a high-quality business, its growth outlook appears subdued. With earnings largely tied to the domestic economy and interest rate movements, it is hard to see where the next big leg of expansion will come from.

For investors thinking long term, I believe there are better opportunities elsewhere, and in stocks with scalable business models, global ambitions, and structural tailwinds. Two that stand out to me are listed below.

Pro Medicus Ltd (ASX: PME)

Pro Medicus provides medical imaging software to hospitals and health networks across the United States, Europe, and Australia. Its flagship platform, Visage 7, allows doctors to view and analyse high-resolution medical images quickly and efficiently. This is a capability that has become critical in modern diagnostics.

A key attraction is its business model. It earns recurring revenue through long-term contracts with major healthcare systems, generating high margins, and strong cash flow with minimal capital requirements. Each new contract typically adds incremental profit, meaning growth can scale rapidly.

The good news is that its outlook is as positive as ever. With the global healthcare industry increasingly digitising and imaging volumes rising, the company's sales pipeline remains very strong according to management. It is also expanding into other ologies, giving it an even larger total addressable market. This is in contrast to CBA, which faces limited growth prospects in a mature banking sector.

Morgan Stanley is recommending Pro Medicus to clients. It has an overweight rating and $350.00 price target on its shares.

Temple & Webster Group Ltd (ASX: TPW)

Another ASX stock that could be better than CBA is Temple & Webster. It has become Australia's leading online furniture and homewares retailer.

Online penetration in Australia's furniture market is still relatively low compared to other developed economies. In fact, as of FY 2025, it had only captured 2.7% of the market. This gives Temple & Webster plenty of room to grow as consumers continue shifting their spending habits online. The company is also expanding its offering beyond home furniture, moving into home improvement to capture a larger slice of household spending.

Macquarie believes that this trend can continue. As a result, it recently put an outperform rating and $31.30 price target on its shares.

Motley Fool contributor James Mickleboro has positions in Pro Medicus and Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Pro Medicus and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Growth Shares

Could these ASX stocks be the next decade's quiet compounders?

Analysts are positive on these quality stocks. Let's find out why.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Growth Shares

The high-conviction ASX stocks I'd buy and hold forever

Analysts think these top stocks could be buys with major upside potential.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Growth Shares

Experts rate these 2 ASX growth shares as buys this month!

These stocks are some of the most exciting on the market.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Growth Shares

These 2 ASX growth shares are ideal for Australians

These businesses have a lot of potential. Here’s why…

Read more »

A businessman hugs his computer and smiles.
Growth Shares

3 amazing ASX growth shares to buy and hold until 2035

Analysts think investors should be snapping up these shares in November.

Read more »

A woman and her child plant flower seedlings in a planter box in a green garden setting.
Growth Shares

This fund manager is bullish on these ASX growth shares

Here’s why these small stocks have big potential.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

These top ASX 200 shares could rise 50% to 80%

Analysts are predicting these shares to deliver huge returns over the next 12 months.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Growth Shares

2 ASX stocks that could 10x your $5,000

Analysts think these shares have bright futures and have put buy ratings on them.

Read more »